Is Colgate-Palmolive (CL) overvalued or fairly valued?

MarketChacha shows Colgate-Palmolive's valuation in context — a trailing P/E of about 26.8, a forward P/E of about 22.7, a price-to-book of about 314.7 — alongside its revenue and profit growth and whether reported profit converts into operating cash, so you can judge value for yourself. MarketChacha does not issue ratings, price targets, or buy/sell advice.

Does Colgate-Palmolive's reported profit turn into cash?

Over 3 years, operating cash flow fully covered reported profit — earnings are backed by real cash. MarketChacha computes this cash-conversion check (1.65×) from reported figures — education, not a rating.

What is Colgate-Palmolive's revenue?

Colgate-Palmolive reported revenue of $20.4B for FY2025, with net profit of $2.1B, per official filings.

What is the share price of Colgate-Palmolive (CL)?

Colgate-Palmolive last traded at $93.15 (-0.1% on the day), as of 8/10/2026 — a delayed quote shown for education, not investment advice.

Colgate-Palmolive

CL · NYSE · Consumer Staples · United States

Snapshot

TickerCL

ExchangeNYSE

SectorConsumer Staples

IndustryHousehold & Personal Products

CountryUnited States

Employees33,600

HeadquartersNew York, United States

Websitewww.colgatepalmolive.com

Filings tracked15

About Colgate-Palmolive

Colgate-Palmolive Company, together with its subsidiaries, manufactures and sells consumer products in the United States and internationally. It operates through two segments: Oral, Personal and Home Care; and Pet Nutrition. The Oral, Personal and Home Care segment offers toothpaste, toothbrushes, mouthwash, bar and liquid hand soaps, shower gels, shampoos, conditioners, deodorants and antiperspirants, skin health products, dishwashing detergents, fabric conditioners, household cleaners, and other related items. This segment markets and sells its products under the Colgate, Palmolive, Darlie, elmex, hello, meridol, Sorriso, Tom's of Maine, EltaMD, Filorga, Irish Spring, Lady Speed Stick, PCA SKIN, Protex, Sanex, Softsoap, Speed Stick, Ajax, Axion, Fabuloso, Murphy, Soupline, and Suavitel brands to a range of traditional and eCommerce retailers, wholesalers, and distributors, as well as dentists and skin health professionals. It also offers pharmaceutical products for dentists and other oral health professionals. The Pet Nutrition segment offers pet nutrition products for everyday nutritional needs under the Hill's Science Diet brand; and a range of therapeutic pet products to help nutritionally support dogs and cats in different stages of health under the Hill's Prescription Diet brand; and a fresh pet food sold to pet specialty and other retailers in Australia under Prime100 brand. This segment markets and sells its products through pet supply retailers, veterinarians, and eCommerce retailers. Colgate-Palmolive Company was founded in 1806 and is headquartered in New York, New York.

Who owns it

Insiders0.1%
Institutions87.7%
Public & other12.2%

2,651 institutional holders

Ownership breakdown from public market data.

Top holders

Blackrock Inc.8.77%
Vanguard Capital Management LLC6.55%
State Street Corporation5.90%
Price (T.Rowe) Associates Inc4.23%
Vanguard Portfolio Management LLC2.99%
Geode Capital Management, LLC2.87%
Morgan Stanley2.62%
Bank Of New York Mellon Corporation1.70%

Largest institutional holders — last updated 6/30/2026.

Forensic scorecard

No major accounting red flags in the fundamentals we have — profit is backed by cash and returns look healthy.

Cash conversion1.65×

Over 3 years, operating cash flow fully covered reported profit — earnings are backed by real cash.

Net margin trend11.8% → 10.5%

Margin has held broadly steady over the period — stable profitability.

Return on equity3948.1%

Latest ROE of 3948.1% — capital is generating a healthy return.

Growth qualityrev 2% · PAT -4%

Profit growth is broadly tracking revenue growth — the earnings trend looks operational rather than one-off.

Computed by MarketChacha from reported figures (SEC XBRL). Education, not a rating or recommendation.

What's expected next

Next quarter

Rev $5.4B · EPS 0.97

Est. earnings growth +1.9%

Next fiscal year

Rev $22.1B · EPS 4.10

Est. earnings growth +5.8%

Analyst consensus estimates — not the company's own guidance.

New to these terms?

P/E ROE ROCE Margins Market cap

Browse the Learn hub →

Financials at a glance

Source: SEC XBRL

Annual

Quarterly · last 8

Revenue (FY2025)

$20.4B

Net margin

10.5%

ROE

3948.1%

Revenue CAGR (2y)

+2.3%

Profit CAGR (2y)

-3.7%

EPS (FY2025)

2.63

Net profit (FY2025)

$2.1B

Ask MarketChacha about CL

Get a cited, plain-English answer — the “why”, not just data. Finance research only, never buy/sell advice.

Financials

Yearly

Period	Revenue	Net profit	EPS	Net margin	ROE
FY2025	$20.4B	$2.1B	2.63	10.5%	3948.1%
FY2024	$20.1B	$2.9B	3.51	14.4%	1362.7%
FY2023	$19.5B	$2.3B	2.77	11.8%	377.7%

Quarterly

Period	Revenue	Net profit	EPS	Net margin
2026Q2	$5.4B	$693.0M	0.86	12.9%
2026Q1	$5.3B	$646.0M	0.80	12.1%
2025Q3	$5.1B	$735.0M	0.91	14.3%
2025Q2	$5.1B	$743.0M	0.91	14.5%
2025Q1	$4.9B	$690.0M	0.85	14.1%
2024Q3	$5.0B	$737.0M	0.90	14.6%
2024Q2	$5.1B	$731.0M	0.89	14.5%
2024Q1	$5.1B	$683.0M	0.83	13.5%
2023Q3	$4.9B	$708.0M	0.86	14.4%
2023Q2	$4.8B	$502.0M	0.60	10.4%
2023Q1	$4.8B	$372.0M	0.45	7.8%

Figures as reported, in reporting currency. Source: SEC XBRL.

Filings & announcements

2026

8-K — Results of operations, Exhibits
SEC7/31/2026material
10-Q filing
SEC7/31/2026
8-K — Shareholder vote results
SEC5/13/2026material
8-K — Results of operations, Costs from exit/disposal, Exhibits
SEC5/1/2026material
10-Q filing
SEC5/1/2026
8-K — Executive/director change
SEC4/9/2026material
8-K — Other events, Exhibits
SEC3/17/2026material
8-K — Executive/director change
SEC3/12/2026material
10-K filing
SEC2/23/2026
8-K — Results of operations, Exhibits
SEC1/30/2026material

2025

8-K — Other events, Exhibits
SEC11/10/2025material
8-K — Results of operations, Costs from exit/disposal, Exhibits
SEC10/31/2025material
10-Q filing
SEC10/31/2025
8-K — Results of operations, Costs from exit/disposal, Exhibits
SEC8/1/2025material
10-Q filing
SEC8/1/2025

In the news

Education and discussion only — not investment advice. Financials from official filings (SEC/BSE) and reported company statements; market figures (delayed market data) are delayed and shown for reference only. Verify with the linked sources before acting.